BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19849974)

  • 1. [Mutations in TET2 in myeloid cancers].
    Bernard OA; Delhommeau F; Fontenay M; Vainchenker W
    Med Sci (Paris); 2009 Oct; 25(10):785-8. PubMed ID: 19849974
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutation in TET2 in myeloid cancers.
    Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
    N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
    Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
    Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutation in TET2 in myeloid cancers.
    Tefferi A; Lim KH; Levine R
    N Engl J Med; 2009 Sep; 361(11):1117; author reply 1117-8. PubMed ID: 19741235
    [No Abstract]   [Full Text] [Related]  

  • 5. A common genetic mechanism in malignant bone marrow diseases.
    Levine RL; Carroll M
    N Engl J Med; 2009 May; 360(22):2355-7. PubMed ID: 19474434
    [No Abstract]   [Full Text] [Related]  

  • 6. Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias.
    Couronné L; Lippert E; Andrieux J; Kosmider O; Radford-Weiss I; Penther D; Dastugue N; Mugneret F; Lafage M; Gachard N; Nadal N; Bernard OA; Nguyen-Khac F
    Leukemia; 2010 Jan; 24(1):201-3. PubMed ID: 19710701
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mutation of tet2 gene and malignant blood disease].
    Qian XF; Shen YF; Zhang SJ; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cohesin complex mutations in myeloid neoplasms are enriched for SRSF2, RUNX1, TET2, and NRAS co-mutations and morphologic dysplasia.
    Hirt CK; Padmanabha N; Michaels PD
    Leuk Res; 2023 Sep; 132():107357. PubMed ID: 37481994
    [No Abstract]   [Full Text] [Related]  

  • 9. TET2 mutations in myelodysplasia and myeloid malignancies.
    Mullighan CG
    Nat Genet; 2009 Jul; 41(7):766-7. PubMed ID: 19557078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
    Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms.
    Lin HC; Hwang DY; Lim KH
    Med Oncol; 2016 Aug; 33(8):92. PubMed ID: 27418193
    [No Abstract]   [Full Text] [Related]  

  • 12. Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.
    Scopim-Ribeiro R; Machado-Neto JA; de Melo Campos P; Niemann FS; Lorand-Metze I; Costa FF; Olalla Saad ST; Traina F
    Diagn Pathol; 2016 Mar; 11():28. PubMed ID: 26984174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.
    Janssen JW; Steenvoorden AC; Lyons J; Anger B; Böhlke JU; Bos JL; Seliger H; Bartram CR
    Proc Natl Acad Sci U S A; 1987 Dec; 84(24):9228-32. PubMed ID: 3122217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.
    Mangan JK; Speck NA
    Crit Rev Oncog; 2011; 16(1-2):77-91. PubMed ID: 22150309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
    Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
    Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.
    Tremblay D; Sokol K; Bhalla S; Rampal R; Mascarenhas JO
    Oncology (Williston Park); 2018 Apr; 32(4):e38-e44. PubMed ID: 29684235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Coltro G; Antelo G; Lasho TL; Finke CM; Pardanani A; Gangat N; Carr RM; Binder M; Mangaonkar AA; Ketterling R; Fernandez-Zapico ME; Robertson KD; Bosi A; Vannucchi AM; Tefferi A; Patnaik MM
    Am J Hematol; 2020 Apr; 95(4):E86-E89. PubMed ID: 31925810
    [No Abstract]   [Full Text] [Related]  

  • 19. Consequences of mutant TET2 on clonality and subclonal hierarchy.
    Hirsch CM; Nazha A; Kneen K; Abazeed ME; Meggendorfer M; Przychodzen BP; Nadarajah N; Adema V; Nagata Y; Goyal A; Awada H; Asad MF; Visconte V; Guan Y; Sekeres MA; Olinski R; Jha BK; LaFramboise T; Radivoyevitch T; Haferlach T; Maciejewski JP
    Leukemia; 2018 Aug; 32(8):1751-1761. PubMed ID: 29795413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
    Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
    Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.